Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What is MSI?

Access Course


880309.jpg?interpolation=lanczos-none&resize=300:225Drs Overman and Sinicrope discuss the emergence of MSI-H: what it is, how it may be used to help guide treatment with immunotherapy.

The goal of this activity is to discuss the evolving role of MSI to help guide cancer immunotherapies.


This activity is intended for oncologists, gastroenterologists, and pathologists




Approximate Time to Complete: 30 minutes


Credit Available: Nov. 28, 2017 - Nov. 28, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the definition of microsatellite instability (MSI) in patients with cancer
  • Have increased knowledge regarding the clinical data on the potential utility of MSI as a biomarker in patients being considered for treatment with immune checkpoint inhibitors
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50